Mindbreeze is AI partner of Fabasoft Approve
16.10.2024 16:02:00 CEST | Business Wire | Press release
Redefining document and quality management with artificial intelligence
Software manufacturer Fabasoft Approve is expanding its cloud-based document and quality management system (DMS/QMS) Approve with AI services from Mindbreeze. Customers in the mechanical and plant engineering industry benefit from a smart flow of information in the supply chain and prevent the loss of know-how due to changes in the workforce.
The flexible standard product for industry enables the networking of suppliers and customers in a common data environment. This greatly simplifies information provision and processing. The AI provides contextual information for automated test and approval processes. This reduces the manual effort and ensures efficiency and traceability along the supply chain.
AI assistance at the push of a button
“With Approve, we offer AI assistance at the push of a button. Our customers can access AI support directly in 'Non Conformance Reports' according to CAPA or '8D' without the laborious task of typing in prompts first,” explains Andreas Dangl, entrepreneur and CEO of Fabasoft Approve GmbH. The software then provides precise suggestions for action in "issue management" or helps put together a team of experts to rectify defects.
Mindbreeze analyzes and links information from a host of different internal company data sources, such as service tickets or technical documents. Depending on the requirement, Mindbreeze processes the content in personalized 360-degree views, creates summaries, or delivers answers to questions that have been asked (chat with documents). “In specific application areas, artificial intelligence is already more powerful and efficient than human beings. In particular, tasks containing patterns that can be learned by an AI can be perfectly automated. This frees up the specialists and gives them time for more important tasks,” explains Daniel Fallmann, founder and CEO of Mindbreeze.
More information can be found in the white paper “AI in Practice: Intelligent Document and Quality Management for Industry”
About Mindbreeze
Mindbreeze is a leading provider of AI-based knowledge management solutions with locations in Europe and North America and a global partner network. Mindbreeze InSpire uses generative AI (GenAI) and other artificial intelligence (AI) methods to help companies analyze, understand and efficiently network their business-critical information.
About Fabasoft Approve
Fabasoft Approve GmbH is a European manufacturer of document and quality management software (DMS/QMS) for the industrial sector. Thanks to the simple adaptability via no-code/low-code, customer-specific requirements can be implemented in no time at all. Cross-company processes connect internal and external project partners on a common platform and, supported by AI, digitally map the entire information life cycle for industrial products. Numerous major international companies from the mechanical and plant engineering sector rely on the cloud-based product Approve on Fabasoft PROCECO as a shared data environment in their digitalization strategy.
Additional information can be found in the Fabasoft Approve Press Room, www.fabasoft.com/approve, or follow us on LinkedIn and Twitter @Fabasoft.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240919478727/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom